Crinetics Pharmaceuticals (CRNX) Reports In-Line Q4 EPS

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.88), in-line with the analyst estimate of ($0.88).

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Royal Caribbean Nears Deal For Sandals - FT
• Active options: MSFT SOFI MSTR GME GRAB BAC AVGO NFLX ORCL GOOG
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance